Glutathione Depletion in a Benign Manner by MoS2‐Based Nanoflowers for Enhanced Hypoxia‐Irrelevant Free‐Radical‐Based Cancer Therapy. Issue 51 (21st November 2019)

• Record Type: Journal Article
• Authors: Wu, Si; Liu, Xinping; Ren, Jinsong; Qu, Xiaogang
• Is Part Of: Small. Volume 15:Issue 51(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-11-21
• Subjects: free radicals -- glutathione depletion -- hypoxia‐irrelevant cancer therapy -- molybdenum disulfide; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.201904870
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: Tumor hypoxia significantly diminishes the efficacy of reactive oxygen species (ROS)‐based therapy, mainly because the generation of ROS is highly oxygen dependent. Recently reported hypoxia‐irrelevant radical initiators (AIBIs) exhibit promising potential for cancer therapy under different oxygen tensions. However, overexpressed glutathione (GSH) in cancer cells would potently scavenge the free radicals produced from AIBI before their arrival to the specific site and dramatically limit the therapeutic efficacy. A synergistic antitumor platform (MoS2 @AIBI‐PCM nanoflowers) is constructed by incorporating polyethylene‐glycol‐functionalized molybdenum disulfide (PEG‐MoS2 ) nanoflowers with azo initiator and phase‐change material (PCM). Under near‐infrared laser (NIR) irradiation, the photothermal feature of PEG‐MoS2 induces the decomposition of AIBI to produce free radicals. Furthermore, PEG‐MoS2 can facilitate GSH oxidation without releasing toxic metal ions, greatly promoting tumor apoptosis and avoiding the introduction of toxic metal ions. This is the first example of the use of intelligent MoS2 ‐based nanoflowers as a benign GSH scavenger for enhanced cancer treatment. Abstract : Hypoxia‐irrelevant free‐radical initiator (AIBI) has potential for cancer therapy under different oxygen tensions. However, overexpressed glutathione (GSH) in cancer cells would potently scavenge the free radicals produced from AIBI before their arrival to the specific site and dramatically limit the therapeutic efficacy. Therefore, reduction of intracellular GSH level in a benign manner is sorely needed.